Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), a leading biopharmaceutical company with a market capitalization of $62.17 billion, finds itself at a critical juncture as it navigates challenges to its ...

The company’s product portfolio is anchored by Eylea, used in treating various eye diseases, and Dupixent, which has shown significant growth potential across multiple indications. In the first ...

The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

The company's former top-selling treatment, Eylea, is losing ground to biosimilar competition. Luckily, a next-generation version, Eylea HD, is picking up some of the slack. First-quarter Eylea HD ...

Bayer A.G. (OTCPK:BAYZF) (OTCPK:BAYRY) said that an advisory panel of the European Medicines Agency (EMA), endorsed the label expansion of a high-dose version of its ophthalmic drug, Eylea ...

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related macular ...

Bayer said in a statement the European Medicines Agency recommended that eye drug Eylea, at a high dose of 8 mg, can be injected at intervals of up to six months to treat wet age-related macular ...

Berlin: Bayer has received approval from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for Eylea 8 mg (aflibercept 8 mg) for the treatment of ...

To print, click the 'pop out' button in the top right corner, then use the printer button on the new tab. Note: If it is cutting off the right side of the sheet, go to 'more settings' on the print ...

Scientists in the US have created a way to 3D print materials inside the body using ultrasound. Tests in mice and rabbits suggest the technique could deliver cancer drugs directly to organs and repair ...